KIR3DL1 and acute myeloid leukemia: Next, we evaluated the frequency of inhibitory and activating KIR receptors, HLA-I ligands, and specific KIR/HLA-I ligand interactions in controls and in total patients, as well as in B-ALL, T-ALL, and AML patients independently (Table 2).